Laddar...
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a relatively new class of oral antihyperglycemic agent that enhance insulin secretion by reducing degradation of endogenous glucagon-like peptide 1. Currently, sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin have been approved by the U...
Sparad:
| Huvudupphovsmän: | , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
SAGE Publications
2014
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4110853/ https://ncbi.nlm.nih.gov/pubmed/25083269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098614523031 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|